A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.

Wipro and Intel backed customer experience platform developer Lilt's $55m series C while Pfizer is buying corporate-backed respiratory virus therapeutic developer ReViral for up to $525m.

Kraken, OK Group, 9fBank and Baofoo are in line to exit Wyre, with its cryptocurrency infrastructure technology to strengthen Bolt's one-click checkout offering.

Mitsui took part in oncology therapy developer Ensem Therapeutics' $67m series A round while Bioventus is paying up to $450m to buy the rest of portfolio company CartiHeal.

The Stripe-backed rapid checkout tool developer was valued at $1bn early last year but is closing its doors after failing to raise more cash.

The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

Crypto.com, Huobi and BitMart invested in cryptocurrency scaling technology developer Boba Network at a $1.5bn valuation while natural fibre composite provider Bcomp netted $34.9m in a BMW-led round.

HPE, Alphabet, Ericsson, Qualcomm, Oracle, Liberty Global and NetApp are set to exit the edge computing technology provider.

The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.